Gilead spent most of the 2010s as the company that cured hepatitis C, then watched that revenue stream shrink as it ran out of patients to cure. The pivot to HIV maintenance drugs bought time. The $21 billion purchase of Immunomedics in 2020 bought an oncology story. Now, after a run of acquisitions totaling more than $11 billion in the first nine months of 2026 alone, the stock hit an all-time high of $175.65 on November 1. The question worth asking at a peak is always the same: what does this price already believe?
We took the three claims circulating most loudly after the Q3 2026 earnings release and held each one against the filed numbers. The math (what the filings justify) and the mood (what the market is currently paying) do not always agree. Here is where they do, where they don’t, and what is genuinely unknowable.
What matters here
The filed numbers show a business growing faster than it has in years, with gross margins above 80% and a raised revenue outlook. The stock’s price-to-sales ratio is at the highest point in our decade of data, meaning the mood has priced in a great deal of that improvement already. The open question is whether HIV franchise growth holds through a known Medicare price cut arriving in 2028, and whether a pipeline spending spree worth more than the whole company earns in a year produces returns. Those two readings cannot both be ignored, and the gap between them is the story.
Claim 1: “The HIV business has never been stronger”
This one is largely true, and the filings say so plainly. HIV product sales reached $6.2 billion in Q3 2026, up 18% from the same quarter a year earlier. Biktarvy, the flagship daily pill, now holds a majority of the U.S. market at an all-time high share. Yeztugo, a twice-yearly injectable for HIV prevention launched in mid-2025, is on track for roughly $1 billion in 2026 sales after generating $150 million in all of 2025. That is a product going from a standing start to blockbuster territory in about eighteen months.
The complication, flagged by RBC Capital Markets analyst Brian Abrahams and reported by Barchart, is that some of Q3’s HIV growth reflects inventory build rather than patient demand, and that Biktarvy faces a steep Medicare price reduction starting January 2028 under the Inflation Reduction Act. The drug’s patent runs to 2033, so the revenue cliff is policy-made, not patent-made. That cut is projected to reduce 2028 sales by roughly $1.5 billion, about a quarter of what the HIV segment earns in a single quarter today.
The HIV story is genuinely strong right now. The filed numbers support that. What they also show is a known, dated event that will reset the franchise’s economics in about fourteen months, and the mood does not appear to be discounting it heavily.
Claim 2: “The oncology pivot is working”
Trodelvy, the drug Gilead acquired with Immunomedics, posted $506 million in Q3 2026 sales, up 42% year-over-year. It received FDA approval in Q2 2026 for a new use in triple-negative breast cancer, expanding its addressable market. An FDA decision on anito-cel, a cell therapy for multiple myeloma, is expected in December 2026. These are real regulatory wins, not projections.
The counterweight sits in the same filing. Cell therapy sales fell meaningfully year-over-year in Q3 2026, a trend the dossier describes as likely to continue as competition intensifies. Merck’s Keytruda franchise alone generated more in a single quarter than Gilead’s entire oncology segment earns in a year. Johnson & Johnson’s Innovative Medicine segment generates multiples of Gilead’s entire oncology revenue each quarter. Gilead is building a real oncology business, but it is building it against opponents whose scale dwarfs its current position.
More striking is the cost of the build. Acquired in-process R&D charges, the accounting term for what a company pays when it buys a drug that has not yet been approved (expensed immediately rather than spread over time), totaled $11.3 billion for the nine months ended September 30, 2026, per the Q3 10-Q. That is a sum larger than Gilead’s entire oncology and liver disease segments combined, spent in three quarters. It is why the company guides to a GAAP loss per share for the full year even as the underlying business earns well. A household analogy: imagine a family that spent well beyond its annual income on a home renovation, then told you the renovation was an investment. It might be. But the bill is real and the return is not yet.
The oncology pivot is producing revenue growth. Whether the acquisitions producing that growth were priced sensibly is a question the filings raise but cannot yet answer.
Claim 3: “The stock is reasonably valued given the growth”
This is where the math and the mood diverge most sharply. Needham raised its valuation estimate to $200 and Cantor Fitzgerald to $175, both on October 30, per Barchart. A Seeking Alpha piece published the same day argued the opposite: that “the valuation no longer works” given the Medicare pricing problem and inventory-inflated HIV numbers.
Our data puts the tension in a single comparison. Gilead’s price-to-sales ratio, which measures what the market pays for each dollar of revenue (a useful gauge when earnings are distorted by one-time charges), sits at 6.7 times. The median for this stock over the past decade is 3.6 times. The current reading is at the 100th percentile of its own history, meaning it has never been this expensive relative to sales. The P/E ratio measured against non-GAAP earnings is more moderate, sitting in the middle of its decade range.
Full-year 2026 non-GAAP EPS guidance of $8.75 to $9.10, per the updated guidance released October 29, is a genuine improvement over the prior year, and the consensus analyst estimate for 2027 is higher still, per valueinvesting.io. If those estimates prove accurate and the stock trades at its decade-median earnings multiple, the implied level would sit meaningfully below today’s price. If growth sustains and the multiple holds, the mood wins. The filings cannot resolve that; only time can.
Reading the numbers
$8.3 billion in Q3 2026 product sales, up 13% year-over-year. This is what the business brought in from selling drugs in a single quarter. Thirteen percent growth means the company added revenue roughly equal to a mid-sized pharmaceutical company’s entire quarterly output. It matters because it confirms the top-line story is real, not accounting-driven.
81.0% product gross margin (GAAP), Q3 2026. A gross margin is what remains of each dollar of sales after the direct cost of making the product. At 81 cents on every dollar, Gilead keeps more of each sale than almost any manufacturer outside software. A grocery store keeps roughly 25 cents. This margin is the engine that funds the R&D spending without immediately destroying cash flow.
$11.3 billion in acquired in-process R&D charges, nine months ended September 30, 2026. Think of this as the price tag for buying drugs that are not yet approved. Accounting rules require the full cost to be recorded immediately. A household equivalent: paying $110,000 upfront for a contractor who promises to build a room that may or may not pass inspection. The room might be worth it. The check has already cleared.
Price-to-sales ratio of 6.7 versus a decade median of 3.6. For every dollar Gilead earns in annual revenue, the market is currently paying $6.70. Historically it has paid $3.60. That gap means the mood is paying a premium that requires the growth story to hold, the pipeline to deliver, and the Medicare headwind to be manageable. All three conditions must be met simultaneously.
For the standing yardsticks on Gilead Sciences: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Gilead Sciences.
Sources
- Gilead Q3 2026 earnings release
- 10-Q for quarter ended September 30, 2026
- 10-K for fiscal year ended December 31, 2025
- 10-K for fiscal year ended December 31, 2024
- GuruFocus: Gilead raises 2026 revenue guidance
- Barchart: Q3 deep dive, HIV franchise and policy headwinds
- TradingView: GILD all-time high, November 1, 2026
- ValueInvesting.io: GILD consensus estimates
- MarketScreener: Q3 2026 prepared remarks summary
- StreetInsider: Gilead tops Q3 EPS, revises guidance
